Janssen Bets On Simeprevir For HCV In China; Partners With Hepatology Society
This article was originally published in PharmAsia News
Executive Summary
It may take four to five years for next-generation oral hepatitis C therapies to take hold in China, and Johnson & Johnson subsidiary Janssen Inc. isn’t wasting any time stepping up efforts to increase disease awareness via partnerships.
You may also be interested in...
Gilead Maintaining Lead Position In Hepatitis C, While Idenix Is Starting Over
Gilead and AbbVie are seen as running neck-and-neck to bring the first all-oral combo of direct-acting antivirals to market in HCV, but Gilead’s regimen is expected to win a larger market share. Idenix is starting over in the nucleoside space, but expects to bring a uridine-based “nuc” into clinical development by mid-year.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.